Maine lawmakers vote against cell phone warning label

The Health and Human Services Committee of Maine's Legislature voted 8-5 on Tuesday not to require labels on cell phones warning consumers that they may emit cancer-causing radiation, citing a dearth of credible scientific evidence and a preference for not causing panic among the state's consumers, according to the Bangor Daily News.

The bill, LD 1706, "An Act to Create the Children’s Wireless Protection Act" proposed the following warning label:

  • "WARNING, THIS DEVICE EMITS ELECTROMAGNETIC RADIATION, EXPOSURE TO WHICH MAY CAUSE BRAIN CANCER. USERS, ESPECIALLY CHILDREN AND PREGNANT WOMEN, SHOULD KEEP THIS DEVICE AWAY FROM THE HEAD AND BODY."

While legislators shied away from the warning label itself, they did call on the Maine Center for Disease Control and Prevention to take the lead in establishing a public awareness campaign regarding cancers and cell phone use.

By Ross Bonander

LD 1706 (PDF file)

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap